Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation
Authors' conclusion
Aspirin compared with clopidogrel was associated with similar cardiovascular and bleeding outcomes beyond 30 days and up to 1 year after percutaneous coronary intervention regardless of OAC at discharge.
Study context
- Population
- Patients after PCI in the STOPDAPT-3 trial, with or without oral anticoagulation (OAC) at discharge788 (13.6%) with OAC
- Participants
- 5,809 patients
- Comparison
- Aspirin vs clopidogrel beyond 1 month after PCI, with or without OAC
- Primary endpoint
- Coprimary: CV end point (CV death, MI, definite stent thrombosis or ischemic stroke) and bleeding end point (BARC 3 or 5)
- Follow-up
- Beyond 30 days up to 1 year
Methodological detailssubgroup analysis stratified by OAC, 30-day landmark analysis
- Subgroup analysis stratified by OAC
- 30-day landmark analysis
Primary result
As reported in the abstract
Aspirin vs ClopidogrelHazard ratio (95% CI)
CV end point, OAC: 3.7% vs 3.9%
0.92(0.44–1.93)
CV end point, no OAC: 3.7% vs 3.6%
1.03(0.77–1.38)
Bleeding end point, OAC: 3.5% vs 4.2%
0.82(0.39–1.73)
Bleeding end point, no OAC: 1.5% vs 1.4%
1.07(0.66–1.72)
Original publication
Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation. Circ Cardiovasc Interv. Published 24 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →